A record of what Choice Institutional Equities Analysis said publicly, with the source. Not advice.
“Upgraded Lupin to 'Buy' with a target price of ₹2,375, citing continued growth momentum in North America and India, along with high-impact launches like Liraglutide and Glucagon. While FY26 margins may face temporary pressure from increased R&D on the GLP-1 portfolio, normalisation is expected by FY27 as scale benefits kick in. Forecasts revenue, EBITDA, and PAT CAGR of 12%, 14%, and 12% respectively over FY25–28E.”
Choice Institutional Equities Analysis’s track record (trackable calls only): 77 graded calls · 95% CI 35–57%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹2,375, as stated.
Window: 12 months, the default when no time frame is stated.
The target ₹2,375 was reached on a close. Hit.
The grader’s working: R4 TARGET_CALL: entered ₹1918 on 2025-08-08 (next trading session's close); target ₹2375 reached at close ₹2442.9 on 2026-05-06. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was reached on a close 179 trading sessions (271 calendar days) after the entry.
- Worst close against it
- The closing price went as far as 1.48% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.